- Home
- BBIO
as 07-31-2025 10:31am EST
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Upcoming Earnings Alert:
Get ready for potential market movements as BridgeBio Pharma Inc. BBIO prepares to release earnings report on 05 Aug 2025.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 8.8B | IPO Year: | 2019 |
| Target Price: | $61.50 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.72 - $48.68 | Next Earning Date: | 08-05-2025 |
| Revenue: | $127,415,000 | Revenue Growth: | -41.71% |
| Revenue Growth (this year): | 106.33% | Revenue Growth (next year): | 54.30% |
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Valantine Hannah | BBIO | Director | Jun 10 '25 | Sell | $40.00 | 4,292 | $171,680.00 | 1,764 | |
| Kumar Neil | BBIO | Chief Executive Officer | May 16 '25 | Sell | $33.49 | 101,156 | $3,376,741.11 | 217,804 | |
| KKR Genetic Disorder L.P. | BBIO | 10% Owner | May 12 '25 | Sell | $34.20 | 6,000,000 | $205,200,000.00 | 13,260,971 | |
| Lo Andrew | BBIO | Director | May 2 '25 | Sell | $38.50 | 100,000 | $3,849,900.00 | 105,583 | |
| Apuli Maricel | BBIO | Chief Accounting Officer | May 2 '25 | Sell | $38.51 | 1,026 | $39,509.11 | 147,639 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
BridgeBio Pharma Sells Part of Beyonttra Royalty Rights for $300 Million
GlobeNewswire
a month ago
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
MT Newswires
a month ago
BridgeBio Pharma Insider Sold Shares Worth $4,422,800, According to a Recent SEC Filing
GlobeNewswire
a month ago
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
TipRanks
a month ago
TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks That Are Ticking Every Box
Insider Monkey
a month ago
Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results
Insider Monkey
a month ago
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform’ Rating
MT Newswires
a month ago
Wolfe Research Initiates Coverage on BridgeBio Pharma With Outperform Rating, $49 Price Target
Compare BBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.